Tarsus Pharmaceuticals is partnering with celebrity John Cena on a campaign to raise awareness of Demodex blepharitis. As part of this campaign, Cena will detail his own experience with Demodex blepharitis and lotilaner ophthalmic solution 0.25% (Xdemvy) the first FDA-approved treatment that directly targets and kills the mites that cause Demodex blepharitis.
“I suffered from eyelid redness, itching and crusting for years, chalking it up to long days on set under bright lights,” said Cena. “But it finally got to the point where I couldn’t ignore it any longer. My eye doctor diagnosed me with Demodex blepharitis, and I was relieved to finally understand what was causing my symptoms and to know there was an available treatment. After being prescribed Xdemvy, my eyelid mites were eliminated and my symptoms resolved. I’ve spent years pushing my body to the limit, but I hadn’t paid attention to my eye health. Now, I make eye exams a regular part of my routine.”
Demodex blepharitis can be diagnosed during a routine eye examination, when an eye care provider asks the patient to look down to examine the eyelid margin for the presence of collarettes (ie, crusting).
The campaign will roll out in the coming months via media interviews and social content highlighting Cena’s experience with eyelid mites, his experience with Xdemvy, and his commitment to eye health.
“Too often, people ignore or even accept common eye symptoms like redness, itching and irritation, without realizing they may signal an underlying, treatable condition,” said Bobby Azamian, MD, PhD, Chief Executive Officer and Chairman of Tarsus. “John’s story is relatable to millions who often overlook or neglect their eye health, and his candid perspective and understated humor help bring attention to a significant disease. Regular eye examinations are critical, and we hope his experience encourages more people to recognize the signs, seek care and take their eye health seriously.”
For more information about Demodex blepharitis and Xdemvy, visit www.XDEMVY.com.
